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Abstract
Loss of function of the FMR1 gene leads to fragile X syndrome
(FXS), the most common form of intellectual disability. The loss of
FMR1 function is usually caused by epigenetic silencing of the
FMR1 promoter leading to expansion and subsequent methylation
of a CGG repeat in the 50 untranslated region. Very few coding
sequence variations have been experimentally characterized and
shown to be causal to the disease. Here, we describe a novel FMR1
mutation and reveal an unexpected nuclear export function for
the C-terminus of FMRP. We screened a cohort of patients with
typical FXS symptoms who tested negative for CGG repeat expan-
sion in the FMR1 locus. In one patient, we identified a guanine
insertion in FMR1 exon 15. This mutation alters the open reading
frame creating a short novel C-terminal sequence, followed by a
stop codon. We find that this novel peptide encodes a functional
nuclear localization signal (NLS) targeting the patient FMRP to the
nucleolus in human cells. We also reveal an evolutionarily
conserved nuclear export function associated with the endogenous
C-terminus of FMRP. In vivo analyses in Drosophila demonstrate that
a patient-mimetic mutation alters the localization and function of
Dfmrp in neurons, leading to neomorphic neuronal phenotypes.
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Introduction
Fragile X syndrome (FXS [MIM 300624]) is a highly prevalent,
inherited disorder in humans causing intellectual disability
accompanied by a spectrum of behavioral and physical abnormalities
(Penagarikano et al, 2007). FXS patients typically show develop-
mental delay and display an IQ below 70 and may suffer from
significant decline in short-term memory, executive function,
visuo-spatial abilities, and linguistic processing (Crowe & Hay,
1990; Belser & Sudhalter, 2001; Fisch et al, 2002; Cornish et al,
2004; Loesch et al, 2004). In most cases, the cognitive defects are
accompanied by autistic behavioral phenotypes, including hyper-
reactivity, social anxiety, aggression, stereotypic movements, mood
disturbance, and attention deficiency (Lachiewicz & Dawson, 1994;
Lachiewicz et al, 1994). Sleep disorders and vulnerability to epilep-
tic seizures have also been reported in association with FXS (Berry-
Kravis, 2002; Kronk et al, 2010). In the diagnosis of FXS, clinicians
routinely screen for large expansions of the polymorphic CGG repeat
elements in the FMR1 locus (Xq27.3 [MIM 309550]). In FXS, the
naturally occurring CGG repeats are expanded to numbers above
200, which usually leads to hypermethylation of the repeat itself
and the upstream FMR1 promoter (Fu et al, 1991; Oberle et al,
1991; Pieretti et al, 1991; Verkerk et al, 1991). As a consequence,
the FMR1 is transcriptionally silenced, and no protein product
(FMRP) is formed.
FMRP is an RNA-binding protein that regulates many aspects of
RNA biology, including RNA transport, stability and, most impor-
tantly, mRNA translation (Bagni & Greenough, 2005; Bassell &
Warren, 2008). FMRP is ubiquitously expressed and is particularly
abundant in the brain, ovaries and testes (Devys et al, 1993; Bakker
et al, 2000), and a large number of potential FMRP mRNA and
noncoding RNA targets exist (Fernandez et al, 2013). Collective
evidence from mouse and fruit fly models indicates that local trans-
lational dysregulation in the absence of FMRP can impair early
neuronal development, circuit formation, neurotransmission, and
synaptic plasticity (Bassell & Warren, 2008; Zhang et al, 2001;
Reeve et al, 2005).
Expansion of promoter-proximal CGG repeats and the conse-
quent epigenetic suppression of FMR1 expression is the leading
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genetic mechanism underlying FMRP deficiency in FXS patients.
Deletions within or across the FMR1 locus can also lead to the loss
of FMRP, as reported in several fragile X case studies in the litera-
ture (Gedeon et al, 1992; Wohrle et al, 1992; Tarleton et al, 1993;
Lugenbeel et al, 1995; Coffee et al, 2008). Although these two
genetic mechanisms account for the majority of FXS patients, they
do not usually yield insight into the functional properties of the
different FMRP domains in a clinically relevant context. Pathogenic
FMR1 sequence variants that affect FMRP expression, localization,
and function may also result in FXS. However, only a few poten-
tially pathogenic point mutations in FMR1 have so far been
described (De Boulle et al, 1993; Collins et al, 2010a,b; Gronskov
et al, 2011), and there is a need for detailed genetic and functional
analyses to fully characterize these intragenic mutations. One nota-
ble exception that has yielded important information on the RNA-
binding activity of FMRP is the I304N point mutation, identified in
the FMR1 coding sequence of a FXS patient with severe symptoms
(De Boulle et al, 1993). This particular FMR1 allele has been investi-
gated extensively in numerous studies, and the mutation was found
to profoundly alter many aspects of FMRP function via its effect on
one of the RNA-binding domains called the K homology (KH)
domain (Siomi et al, 1994; Feng et al, 1997; Tamanini et al, 1999;
Laggerbauer et al, 2001; Schrier et al, 2004).
Despite its seemingly low occurrence in the FXS patient popula-
tion (Collins et al, 2010b), searching and screening for potentially
pathogenic FMR1 sequence variants is essential. A segment of the
patient population could otherwise remain undiagnosed and there-
fore may not benefit from future therapies. Moreover, elucidating
the functional consequences of these mutations will provide the
opportunity to study FMRP domains by identifying critical residues
and characterizing the function of different domains in a clinically
relevant context, as demonstrated by the I304N point mutation. The
fact that genetic screens in the D. melanogaster dfmr1 identified
loss-of-function mutations in conserved residues (Reeve et al, 2008)
lends credence to this notion.
Here, we report a novel FMR1 frameshift mutation found in a
patient with FXS symptoms. This mutation alters the open reading
frame, creating a short novel amino acid sequence in the C-terminus
followed by a premature stop codon. Functional characterization of
this patient FMR1 allele reveals that the mutation targets the protein
to the nucleolus in cultured human and mouse cells. Furthermore,
we observe the nuclear retention of the patient FMR1 protein only
when the C-terminus is truncated, hinting at the presence of a novel
nuclear export function in the C-terminus of FMRP. A genetically
versatile model for FMR1 loss of function has been established in the
fruit fly Drosophila melanogaster. The fly has a single homologue of
FMR1, and its loss of function causes many phenotypes similar to
those associated with FXS patients (Zhang et al, 2001; Morales et al,
2002; Pan et al, 2004; Reeve et al, 2005; Bassell & Warren, 2008;
McBride et al, 2012). Using this model for in vivo analyses, we find
that the NLS signal identified in the patient FMRP can target fly dfmr1
protein to the nucleus in fly neurons, also in a C-terminus dependent
fashion. This suggests that the nuclear export function of the FMRP
C-terminus is evolutionarily conserved. Interestingly, the change in
Dfmrp localization alters its function in neurons and leads to
neomorphic phenotypes in vivo. Taken together, our results provide
evidence for changes in FMRP regulation and function brought on by
this novel fragile X patient mutation.
Results
Novel frameshift mutation identified in FXS patient
We selected 16 individuals from our in-house cohort of male
patients with intellectual disability, for sequencing analysis of the
FMR1. The selection was based on the presence of typical neuro-
developmental features of fragile X syndrome including moderate
intellectual disability (IQ < 60), autistic and/or stereotypic behavior,
and impaired social interaction, associated with at least one of the
following physical features: elongated face, macroorchidism, and/or
large ears. The typical CGG repeat expansion in the FMR1 locus was
absent in all 16 males.
Among screened individuals, we found seven with previously
unreported variations in the FMR1 (Supplementary Fig S1A). In 5
of these individuals, single base polymorphisms were identified in
intronic regions. In the other 2, single mutations were present in
coding exons. In one of these individuals, we recovered a silent
base substitution in exon 15. In the other, we identified a guanine
insertion in exon 15 [1457insG] (Supplementary Fig S1A and B).
This G-insertion mutation alters the open reading frame to one
that is not used by any of the alternative FMR1 isoforms (Ensembl
Genome Browser), and is predicted to create a novel peptide
sequence followed by a premature stop codon, which results in
the truncation of the C-terminus of FMRP (Fig 1A). This modifica-
tion also leads to the disruption of the RGG box, one of the three
RNA-binding domains characterized in FMRP (Darnell et al, 2001;
Ramos et al, 2003; Bagni & Greenough, 2005; Blackwell et al,
2010).
The FMR1 allele with the G-insertion mutation was identified in a
male patient with moderate to severe intellectual disability, first
seen at the age of 36 years in a residential care setting (Fig 1B). He
was born to healthy unrelated parents—now deceased—and has
one healthy brother. He went to a specialized school for disabled
children, and IQ measured at adult age was 41. Clinical examination
at age 36 showed a man with normal build and growth parameters
(50th percentile). He made almost no eye contact and had macro-
orchidism with bilateral testicular volume of 30 ml. His behavior
was rather calm, yet periodic aggressive outbursts were noted. Over-
all, he presented with a typical fragile X clinical phenotype,
although the CGG repeat number was reported normal (41 repeats)
in multiple testing rounds.
FMR1 mRNA and protein levels are decreased in
patient-derived cells
To determine whether FMR1 mRNA and protein levels were affected
by the G-insertion mutation, we established an immortalized EBV
lymphocyte line from a blood sample of the patient and measured
FMR1 mRNA and protein levels in these cells. We found both to be
significantly decreased (by ~60 and > 90%, respectively) compared
to the levels in control cells (Fig 1C). We determined that the reduc-
tion of the FMR1 mRNA in patient cells is primarily due to
nonsense-mediated decay (NMD)—a translation-coupled endoge-
nous mechanism to degrade faulty mRNAs with premature stop
codons—since FMR1 mRNA levels in the patient cells were restored
to control levels upon treatment with the translational inhibitor
puromycin (Fig 1C). Western blot analysis indicated that FMRP
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protein levels in patient-derived cells were significantly decreased
compared to control cells from a healthy individual with no CGG
repeat expansion in the FMR1 locus (Fig 1D).
Patient FMRP shows altered cellular localization
To functionally characterize the patient FMRP protein, we began by
expressing this novel allele in human cells. We transfected HEK293
cells with constructs expressing either GFP-tagged wild-type FMRP
(GFP-FMR1WT) or GFP-tagged patient FMRP (GFP-FMR1G-ins) under
the control of a b-actin promoter. While wild-type FMRP was
localized predominantly in the cytoplasm as expected, the patient
FMRP showed a surprising localization pattern that was not
observed with the wild-type protein (Fig 2A). Specifically, the
patient FMRP forms bright nuclear inclusions with 100% pene-
trance. Given their size and appearance, we speculated that these
inclusions might correspond to a nucleolar aggregation of FMRP.
To test this idea, HEK293 cells expressing either GFP-FMR1WT or
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Figure 1. Novel G-insertion mutation identified in male with FXS symptoms.
A Predicted effects of the G-insertion mutation on FMRP are schematized. The insertion site corresponds to the beginning of the RNA-binding RGG Box, where it alters
the open reading frame and thus disrupts the domain entirely. The frameshift creates a novel peptide sequence [RKRTRRKRTWRRLQRKRRSLPNR] followed by a
premature stop codon, causing the truncation of the FMRP C-terminus.
B Photograph of male patient with FMR1G-ins. allele. Typical physical and behavioral features of FXS were noted in the patient, who shows moderate to severe
intellectual disability.
C FMR1 mRNA levels were analyzed via RT–qPCR in EBV-transformed lymphocyte cells derived from the patient’s blood samples. Patient cells showed a ~60% decrease
in FMR1 mRNA compared to control cells (*P = 0.010, 0.383  0.110 SD, n = 3). Treatment with translational blocker puromycin restored FMR1 mRNA levels in
patient cells (*P = 0.048, 0.383  0.110 SD versus 1.25  0.166 SD, n = 3), suggesting that the reduction of FMR1 mRNA in these cells is primarily due to nonsense-
mediated decay. RT-qPCR reactions were run in triplicate in three independent experiments. Fold changes in FMR1 expression, normalized to HRPT expression,
were calculated using the DDCT method, and analyzed statistically with a two-tailed t-test (GraphPad). Error bars represent mean values with SD.
D Western blot analysis shows a significant decrease (> 90%) in FMRP protein levels in patient-derived cells (***P = 0.008, 0.13  0.031 SD, n = 2), and the patient
FMRP migrates slightly lower than the wild-type protein. Band intensities for the different cell lines were quantified, normalized for actin and analyzed statistically
with a twot-tailed t-test (GraphPad). Error bars represent mean values with SD.
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Figure 2. Patient FMRP aggregates in the nucleolus.
A–C HEK293 (A) and SH-Sy5y (B) cells, as well as primary neurons from FMR1 KO mice (C), were transfected with vectors encoding the GFP-tagged wild-type FMRP (GFP-
FMR1WT) or the GFP-tagged patient FMRP (GFP-FMR1G-insertion) under the control of a b-actin promoter. Wild-type FMRP localizes predominantly in the cytoplasm,
whereas the patient FMRP forms nuclear and nucleolar aggregates that colocalize with nucleophosmin. Scale bars in (A, B) represent 10 lm. Scale bar in (C)
represents 5 lm.
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GFP-FMR1G-ins were stained for the detection of a nucleolar specific
protein, nucleophosmin (NPM1). We found that the patient FMRP,
unlike its wild-type counterpart, colocalizes with nucleophosmin,
confirming the novel nucleolar localization of the patient FMRP.
Finally, expression in SH-Sy5y human neuroblastoma cells (Fig 2B)
as well as primary cultures of FMR1-KO mouse neurons resulted in
a similar nuclear and nucleolar localization pattern for the patient
FMRP, albeit at lower levels (Fig 2C).
The frameshifted C-terminus contains a nuclear
localization signal
We sought to explore the peptide changes in the patient FMRP that
could target the protein to the nucleus. The G-insertion mutation and
the accompanying frameshift lead to two significant modifications of
the FMR1 protein (Fig 1A): (i) the truncation of the C-terminus and
(ii) the presence of a novel, 22 amino acid peptide sequence—both
of which may contribute to the altered localization pattern. We
therefore dissected and characterized the contribution of each of the
two components separately. We found that the C-terminus trunca-
tion (GFP-FMR1DCt) alone did not result in nuclear retention of FMRP
(Fig 3A), suggesting that the novel amino acid sequence in the
patient FMRP directs the change in localization observed. Interest-
ingly, this novel peptide sequence is predicted to be a bipartite
nuclear localization signal (NLS) when analyzed with the Scan-
Prosite tool from Expasy (de Castro et al, 2006). This motif scanner
identifies the NLS based on the adjacent stretches of Arg and Lys
(Fig 1A). When we mutated adjacent Arg and Lys residues of the
putative NLS to Ala (GFP-FMR1G-ins [NLS mutated]), the nuclear localiza-
tion of the protein was no longer visible (Fig 3B). These results indi-
cate that the novel peptide sequence in the patient FMRP is a
functional nuclear localization signal. This was further confirmed by
showing that the putative NLS could also target the cytoplasmic
protein profilin to the nucleus (Supplementary Fig S2A). Impor-
tantly, the change in subcellular localization of the patient protein
compared to the various controls does not correlate with levels of
GFP-FMR1 Ct
Hoechst B23GFP
FMRPA 
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GFP-FMR1G-ins. (NLS mutated) [Arg/Lys to Ala]
FMRP
RKRTRRKRTWRRLQRKRRSLPNR
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Figure 3. Patient FMRP contains a novel nuclear localization signal in the C-terminus.
A Transfected HEK293 cells expressing a GFP-tagged FMRP in which the C-terminus is truncated following the G-ins. mutation site (GFP-FMR1DCt). GFP-FMR1DCt protein
is exclusively cytoplasmic, suggesting that the truncation of the C-terminus alone is not sufficient to explain the localization change observed for the patient FMRP.
B Transfected HEK293 cells expressing a modified version of GFP-tagged patient FMRP (GFP-FMR1G-ins. [NLS mutated]). The novel amino acid sequence in the C-terminus of
patient FMRP [RKRTRRKRTWRRLQRKRRSLPNR] contains stretches of arginines and lysines predicted to function as a nuclear localization signal (based on Expasy
protein motif scanner, ScanProsite). Mutating adjacent R and K residues into alanines [RARTRAARTWARLQRAARSLPNR] abolishes the nucleolar localization of the
patient FMRP, strongly suggesting that the novel amino acid sequence present in the patient FMRP C-terminus is a functional nuclear localization signal (NLS).
Data information: Scale bar represents 10 lm.
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protein expression (Supplementary Fig S2B). Specifically, the patient
mutation exhibits lower expression levels than the wild-type protein
and the C-terminal truncation alone, but comparable levels to the
controls where the NLS is mutated or the C-terminus is restored.
Together, these data suggest that the nucleolar localization is due to
the mutation and not to an increase in expression level.
An intact C-terminus exports patient FMRP out of the nucleus
Our results demonstrate that the frameshift caused by the
G-insertion mutation creates a novel C-terminal peptide that targets
the patient FMRP to the nucleus. However, it is not clear whether
the truncation of the C-terminus contributes to the nuclear retention
of the patient FMRP. To test this, we created an allele where the
patient NLS motif is fused to the C-terminus of the full-length, wild-
type FMR1 protein (GFP-FMR1wt+NLS). Surprisingly, we did not
observe any nuclear FMRP in cells expressing this specific FMR1
allele (Fig 4A). One possible explanation for this observation is that
an intact C-terminus drives the efficient export of the patient FMRP
from the nucleus. To test this, we studied the expression of GFP-
FMR1wt+NLS in HEK293 cells treated with leptomycin B (LMB), a
potent and specific inhibitor of nuclear export (Wolff et al, 1997). It
has been shown that full-length wild-type FMRP does not show
nuclear retention upon LMB treatment (Dury et al, 2013). In
contrast, we find that nucleolar inclusions of the GFP-FMR1wt+NLS
protein became visible upon treatment with LMB (Fig 4A), indicat-
ing that the presence of an intact C-terminus enables the nuclear
export of FMRP bearing the patient NLS motif.
We also created another relevant variant of the patient FMR1
allele, where the frameshift caused by the G-insertion was restored—
via the deletion of a single base pair—immediately before the
premature stop codon (GFP-FMR1G-ins[Ct revert]). At the protein level,
the RGG box is almost entirely disrupted and replaced by the NLS
sequence as in the case of patient FMRP, though the C-terminus
truncation is avoided in this case. In line with our previous observa-
tions, we did not detect FMRP in the nucleus of cells expressing
GFP-FMR1G-ins[Ct revert] (Fig 4B). However, treatment of these cells
with LMB revealed nucleolar inclusions of FMRP (Fig 4B), once
again demonstrating that the C-terminus truncation is critical for the
nuclear retention of patient FMRP.
Taken together, our cell culture experiments demonstrate that
the patient’s G-insertion mutation leads to profound changes in the
FMR1 protein product. The mutation leads to changes in subcellular
localization mediated by the novel sequence and the truncation of
the C-terminus. The data also suggest a potential nuclear export
mechanism associated with the C-terminus of the FMRP protein in
this context.
Patient FMRP sequence changes cause novel neuronal
phenotypes in vivo
FMRP is a member of protein family known as the FXR protein
family (Siomi et al, 1995; Zhang et al, 1995; Kirkpatrick et al,
2001). Although highly similar in their N-terminus, the C-terminus
of the FXR protein family (Supplementary Fig S3) is not conserved
at the sequence level (Kirkpatrick et al, 2001). We therefore
wondered whether the effects of the mutation on the human protein
are conserved in other FMRP homologs, or whether they are human
specific. Therefore, we exploited the Drosophila melanogaster
model, given its genetic tractability and success as a tool to study
neurodevelopmental processes and related disorders (Okray &
Hassan, 2013). The fruit fly has a single FMR1 homolog—dfmr1—
that equally resembles human FMR1 and FXR genes at the amino
acid level (Wan et al, 2000; Morales et al, 2002). Various morpho-
logical, molecular, and behavioral phenotypes relevant to dfmr1
protein function have been described in Drosophila (Zhang et al,
2001; Morales et al, 2002; Pan et al, 2004; Reeve et al, 2005;
Bassell & Warren, 2008; McBride et al, 2012). We selected a well-
characterized neuronal population termed the Lateral Neurons
ventral (LNv)—the fly circadian pacemaker neurons—whose
connectivity phenotype is strongly affected by Dfmrp activity
(Reeve et al, 2005). Specifically, the overexpression of dfmr1 in a
wild-type background causes a consistent phenotype where the
terminal axonal branches of sLNv neurons collapse (Reeve et al,
2005, 2008) (Fig 5A).
We took advantage of this robust assay and used the
UAS-Gal4 binary expression system (Brand & Perrimon, 1993) to
overexpress various dfmr1 alleles and examined changes in the
dfmr1 gain-of-function phenotype in the LNv neurons. We created
transgenic fly lines with different UAS-dfmr1 variants that dissect
the different effects of the G-insertion mutation on the human
FMRP protein (Fig 5B): wild-type dfmr1 (dfmr1wt); C-terminus
truncated dfmr1 (dfmr1DCt); dfmr1 with the patient NLS only
(dfmr1wt+NLS); dfmr1 with both the patient NLS; and a truncated
C-terminus mimicking the patient mutation (dfmr1DCt+NLS). These
variants were all inserted into the same genomic locus to
minimize position effects on levels of transcription.
Overexpression of wild-type dfmr1wt, dfmr1DCt, and dfmr1wt+NLS
leads to collapse of axonal branches in LNv neurons (Fig 6A and B).
These findings suggest that there is no substantial loss in Dfmrp
function associated with the truncation of the C-terminus alone, or
with the presence of the NLS motif alone, despite significant differ-
ences in protein levels (Supplementary Fig S4). On the other hand,
overexpression of dfmr1DCt+NLS—where both modifications are pres-
ent simultaneously—fails to induce the collapse of LNv axonal
branches (Fig 6A and B). Instead, we detected novel axonal misguid-
ance phenotypes with the overexpression of this allele, including
aberrant bifurcations of axonal bundle termini, “tangles” of axons
failing to extend medially, and misguided projections of single axons
that appear to form loops (Fig 6C). Importantly, the de novo axonal
phenotypes appear despite the fact that DfmrpDCt+NLS is expressed at
lower levels than the wild-type or DfmrpDCt controls, and at compa-
rable levels to the Dfmrpwt+NLS control (Supplementary Fig S4),
consistent with the data for the human counterparts (Supplementary
Fig S2B). Together, these data suggest that the defects caused by the
DfmrpDCt+NLS are an intrinsic property of the compound mutations,
rather than expression levels of the mutant protein.
Finally, we investigated whether the neomorphic axonal pheno-
types associated with dfmr1DCt+NLS correlate with a change in
subcellular localization of the transgenic protein. We found that the
Dfmrp which shows predominantly cytoplasmic localization in fly
neurons (Wan et al, 2000), is targeted to and retained in the nucleus
only when both the NLS motif is present and the C-terminus is
truncated (dfmr1DCt+NLS) (Fig 7A). Neither the truncation of the
C-terminus (dfmr1DCt) nor the presence of the NLS sequence alone
(dfmr1wt+NLS) is sufficient to retain Dfmrp in the nucleus (Fig 7B–D).
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Figure 4. An intact C-terminus facilitates nuclear export of patient FMRP.
A Transfected HEK293 cells expressing GFP-tagged wild-type FMRP fused to the patient NLS motif (GFP-FMR1wt+NLS). Unlike the patient FMRP, GFP-FMR1wt+NLS protein
is predominantly cytoplasmic and does not aggregate in the nucleus. However, treatment of HEK293 cells expressing GFP-FMR1wt+NLS with leptomycin B—an
inhibitor of nuclear export—resulted in the appearance of nucleolar inclusions. This suggests that the presence of a full-length C-terminus facilitates the nuclear
export of FMRP in this context.
B Transfected HEK293 cells expressing a modified version of GFP-tagged patient FMRP, in which the truncation of the C-terminus is reverted by restoring the open
reading frame (GFP-FMR1G-ins.[Ct restored]). The patient protein is not detected in the nucleus when the C-terminus is intact; however, nucleolar retention of the protein
is observed upon leptomycin B treatment of the transfected cells. In line with results from (A), this suggests that an intact C-terminus enables nuclear export of the
FMR1 protein.
Data information: Scale bar represents 10 lm.
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Altogether, these data suggest that the gain of function observed for
the patient-like form of Dfmrp is linked to the nuclear retention of
the protein. Consistent with this idea, further increasing expression
of Dfmrp using two copies of UAS-dfmr1 does not cause nuclear
localization nor axonal looping or bifurcation (Supplementary
Fig S5).
Discussion
Here, we have identified and characterized the effects of a novel,
intragenic FMR1 frameshift mutation discovered in a patient with
typical FXS symptoms. To our knowledge, the G-insertion mutation
reported here is the first naturally occurring, clinically relevant
mutation to significantly alter the localization of FMRP.
The frameshift leads to profound changes in the peptide sequence:
A premature stop codon results in the truncation of the C-terminus,
abolishing the RNA-binding RGG Box, and creates a novel amino
acid sequence encoding a nuclear localization signal (NLS). This NLS
sequence can target the FMRP protein to the nucleolus. Interestingly,
restoring the C-terminus enables efficient nuclear export of the
protein in this context. Finally, using a Drosophila model, we show
that the presence of the NLS sequence together with the truncation
of the C-terminus alters FMRP function in neurons in vivo.
A
Background control
dfmr1 overexpression
B
wt
Ct
wt + NLS
Ct + NLS
RGG 
box
RKRTRRKRTWRRLQRKRRSLPNR
RKRTRRKRTWRRLQRKRRSLPNR
Figure 5. sLNV neurons are sensitive to changes in Dfmrp function.
A The morphology of small lateral ventral neurons (sLNvs) is sensitive to dfmr1 activity. Overexpression of wild-type dfmr1 in the sLNv neurons results in a consistent
“axonal collapse” phenotype, where the branching of axonal termini of sLNvs is reduced. Scale bars represent 50 and 10 lm (magnified images).
B Transgenic fly lines were created bearing UAS-dfmr1 variants, in order to assay in vivo functional changes associated with the effects of the patient mutation: the
truncation of the C-terminus (dfmr1DCt), presence of the patient NLS sequence (dfmr1wt+NLS), or both (dfmr1DCt+NLS).
EMBO Molecular Medicine Vol 7 | No 4 | 2015 ª 2015 The Authors
EMBO Molecular Medicine Clinical FXS mutation uncovers FMRP nuclear export signal Zeynep Okray et al
430
Published online: February 17, 2015 
Our findings strongly support the notion that genetic mecha-
nisms other than CGG repeat expansions and deletions in the FMR1
locus can underlie fragile X syndrome. Although it is likely that the
patient’s symptoms arise from the decrease in FMRP levels, it
cannot be ruled out that impaired and aberrant functions associated
with the remaining mutant protein also contribute. It is worth
noting that males with reduced FMRP levels yet normal range IQs
have been described, indicating that reduction—as opposed to total
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Figure 6. Compound effects of the patient mutation confer a neomorphic function for Dfmrp in sLNV neurons.
A Overexpression of wild-type dfmr1 (UAS-dfmr1wt) using a LNv neuron-specific driver line (Pdf-Gal4) causes reduction of branching area—“axonal collapse”—in the
sLNv axonal termini. dfmr1DCt and dfmr1wt+NLS overexpression phenocopies overexpression of dfmr1wt, suggesting that the truncation of the C-terminus or the
presence of the patient NLS alone does not impair or alter the functional efficacy of dfmr1 in this context. However, overexpression of dfmr1DCt+NLS fails to cause
collapse of sLNv termini, indicating a significant loss or change of Dfmrp protein function. Axonal morphology is visualized by expressing CD8-GFP under the control
of the same neuronal driver. Scale bar represents 10 lm.
B Quantification of axonal termini branching in LNv neurons overexpressing various dfmr1 alleles. Overexpression of dfmr1wt, dfmr1DCt, or dfmr1wt+NLS significantly
reduced axonal branching area [****P < 0.0001; control 101.3  29.76 SD, n = 30; UAS-dfmrwt 45.41  21.69 SD, n = 29; UAS-dfmrDCt 52.31  14.67 SD, n = 32;
UAS-dfmrwt+NLS 72.45  21.83 SD, n = 29; UAS-dfmrDCt+NLS 117.8  36.96 SD, n = 28]. dfmr1DCt+NLS overexpression does not result in a significant change of axonal
branching area compared to the background control [Pdf-Gal4, UAS-GFP] (P = 0.672). For quantification purposes, each branching area (n) was manually outlined,
starting from the first point of defasculation of the axonal bundle. These measurements were normalized for variability in brain size across samples using LNv
commissure length measurements for each brain. Two-tailed t-tests using Welch’s correction were then used to compare controls with mutant phenotypes
(GraphPad). Error bars represent mean values with SD. Dots visible for box plots of UAS-dfmrwt and UAS-dfmrDCt represent samples that outlier the whiskers.
C Overexpression of dfmr1DCt+NLS results in aberrant axonal termini morphology. Axonal guidance defects were frequently observed (arrowheads) and scored manually
for bifurcations of the axon bundle (9/48), tangling of axons in the termini (13/48), and apparent looping of axons (7/48).
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absence—of FMRP is not necessarily always causal to FXS (Hagerman
et al, 1994).
The striking change in localization observed for the patient
FMRP appears to confer a change in function for the protein. The
nucleolar aggregation and retention of the mutant protein could
lead to an exaggeration of a previously proposed (Willemsen
et al, 1996) and recently confirmed (Taha et al, 2014) molecular
function for FMRP: Specific endogenous isoforms have been
detected in trace amounts in the nucleolus, where they biochemi-
cally interact with nucleolin, a multi-functional nucleolar protein
required for rRNA transcription and several steps of ribosome
biogenesis. Despite its subtlety, it is conceivable that localization
of endogenous FMRP to the nucleolus has significant functional
consequences. For example, it is proposed that the combined
action of FMRP and nucleolin in this context can potentially
impact ribosomal biology (Kim et al, 2009; Taha et al, 2014). The
patient FMR1 allele identified in this study may provide a unique
opportunity to gain insight into this unexplored nucleolar function
of FMRP. It is worth noting that in a sense the patient mutation
mimics a reduction of the diversity of FMRP isoforms to a single,
predominantly nucleolar form. Future experiments at endogenous
expression levels in vivo will help ascertain whether these inter-
pretations are true.
Interestingly, the mammalian paralogs of FMR1—the FXR1 [MIM
600819] and FXR2 [MIM 605339] protein products—have been shown
to shuttle between the cytoplasm and nucleolus (Tamanini et al,
1999, 2000). Moreover, cells appear to regulate the nucleolar shuttling
of the FXR1 protein by generating multiple isoforms with different
C-termini, where some isoforms of FXR1 generate a C-terminal
nucleolar localization signal, as a result of a frameshift induced by
alternative splicing of the 30 end of FXR1 mRNA (Tamanini et al,
2000). The fact that the C-terminus is highly variable across FMR/FXR
proteins might suggest that changes in the C-terminus underlie the
functional diversification of the protein family.
A
Pdf-Gal4, UAS-lacZ; UAS-dfmr1 Ct / UAS-RedStinger
Red-Snger merge
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Pdf-Gal4, UAS-lacZ; UAS-dfmr1 CT + NLS / UAS-RedStinger
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D
Dfmrp
Figure 7. Subcellular localization of the Dfmrp variants in sLNv neurons.
A–D Subcellular localization of transgenically expressed dfmr1wt, dfmr1DCt, dfmr1wt+NLS, and dfmr1DCt+NLS proteins in LNv neurons. DfmrpDCt+NLS shows nuclear
localization (A), colocalizing with the genetically encoded nuclear marker RedStinger, while Dfmrpwt, DfmrpDCt, and Dfmrpwt+NLS are predominantly cytoplasmic
(B–D). These results suggest that an intact C-terminus can mediate the nuclear export of the Dfmrp protein. Scale bar represents 5 lm.
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Our findings also highlight the possibility that the FMRP
C-terminus regulates nuclear/nucleolar shuttling of the endogenous
protein. Nuclear shuttling of FMRP has been widely studied,
although the exact mechanisms and protein motifs involved still
remain somewhat unclear (Kim et al, 2009). Despite the fact that
the C-terminus is highly divergent across FMR1 homologs
(Wan et al, 2000; Kirkpatrick et al, 2001), our data suggest that the
nuclear export function mediated by this domain is evolutionarily
conserved.
At any rate, the unique effects of the G-insertion mutation on the
FMR1 protein suggest that future molecular and functional analyses
of the patient allele identified herein can yield crucial insight into
FMRP function in a clinically relevant context.
Materials and Methods
Ethical considerations and patient consents
The clinical screening protocol was approved by the appropriate
Institutional Review Board of the University Hospitals of Leuven
(Belgium), which operates in agreement with the principles in the
WMA Declaration of Helsinki. Informed consent was obtained from
the parents/guardians of the affected patients, and permission to
publish photos of the patient was granted. Mouse housing condi-
tions and experiments were approved by the Dutch Ethical Commit-
tee (DEC) under Erasmus MC Permit Number EMC 140-09-06.
Data deposition
The patient FMR1 variant has been submitted to the Leiden Open
Variation Database (LOVD), with the accession ID #00025860.
CGG repeat analysis and FMR1 sequencing
Genomic DNA from patients was isolated from peripheral blood
according to standard procedures and stored at 4°C. Molecular
FMR1 CGG repeat expansion analyses were performed with an in-
house PCR method and with Southern blot, using probe StB12.3
after a combined EcoRI and EagI digestion, as described in Rousseau
et al (1994). FMR1 locus was amplified from genomic DNA for
Sanger sequencing, performed by VIB Genetic Service Facility (Uni-
versity of Antwerp, Belgium).
Culture and treatment of EBV-transformed lymphoblastoid
cell lines
EBV-transformed lymphoblastoid cell lines were generated from
patient peripheral blood using standard protocols. Cells were propa-
gated as a suspension culture in DMEM/F12 medium containing
10% fetal bovine serum. For experiments involving puromycin, cells
were treated with 200 lg/ml puromycin (Sigma-Aldrich) overnight
(15 h). Cells were washed twice with PBS before RNA extraction.
RNA extraction and RT–qPCR
Total RNA was extracted using TRIzol reagent (Life Technologies),
following the manufacturer’s protocol. The RNA extract was cleaned
up using RNeasy kit (Qiagen). One lg of total RNA was used for
cDNA synthesis (Quantitect Reverse Transcription kit, Qiagen),
providing template for the qPCR. qPCR mixes were prepared using
LightCycler 480 SYBR Green I Master kit (Roche Life Science),
following the manufacturer’s instructions. The qPCR was carried
out using the Roche LightCycler 480 Real-Time PCR System, and
software recommended standard 3-step cycles were used (95°C,
10 s; 60°C, 10 s, and 72°C, 10 s) for 40 cycles. Reactions were run
in triplicate in three independent experiments, where each experi-
ment was analyzed independently, with control (puromycin)
FMR1 levels were set to 1. The mean of expression values of the
housekeeping gene HPRT was used as an internal control to normal-
ize for loading variability. Fold changes in FMR1 expression were
calculated using the DDCT method and analyzed statistically with a
two-tailed t-test (GraphPad). Error bars represent mean values with
SD.
Western blotting
Protein from total cell lysates was resolved in NuPAGE 4–12%
Bis–Tris polyacrylamide gels (Life technologies) under denaturing
conditions and transferred to nitrocellulose membranes (Whatman,
GE Healthcare Life Sciences). The blots were probed using anti-
FMRP antibody (1C3 MAB2160 Millipore), diluted 1:500 in 3%
bovine serum albumin, anti-GFP 1:750 (AB3080; Millipore), and
anti-actin (JLA20 Hybridoma bank or MAB1501 Chemicon) diluted
1:500 or 1:10,000, respectively, in 5% milk. Anti-Dfmrp (5D7) anti-
body was specifically generated by EMBL Monoclonal Antibodies
Core Facility and used in 1:500 dilution in 5% milk. ECL IgG horse-
radish peroxidase-linked antibodies (Amersham, GE Healthcare Life
Sciences) or Li-Cor IRDye antibodies were used as secondary anti-
bodies. Bands were visualized using the ECL Western Blotting
Detection System (GE Healthcare Life Sciences) or the Odyssey
system (Li-Cor). Band intensities for the different cell lines were
quantified using ImageJ software, normalized for actin and analyzed
statistically with a two-tailed t-test (GraphPad). Error bars represent
mean values with SD.
Cloning
We acquired a plasmid in which the GFP-FMR1wt construct was
cloned in a standard mammalian expression vector under a beta-actin
promoter (Levenga et al, 2009). We used this plasmid as template for
generating all FMR1 variant alleles. We modified the FMR1wt insert
using site-directed mutagenesis (QuickChange II Site-directed Muta-
genesis Kit, Stratagene) or (overlap extension) PCR (Phusion poly-
merase, NEB) with classical restriction enzyme cloning.
The fly overexpression constructs were created using the
pUAST-attp-vector backbone. The dfmr1 variants were cloned from
template wt dfmr1 cDNA. We modified the wild-type dfmr1 insert
by using (overlap extension) PCR (Phusion polymerase, NEB) with
classical restriction enzyme cloning.
Cell culture and transfection experiments
Human embryonic kidney (HEK) 293T cells and human neuroblas-
toma SH-SY5Y cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) (Lonza, Verviers, Belgium) supplemented with
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10% fetal bovine serum, 1% penicillin, and 1% streptomycin at
37°C in a 5% CO2 humidified incubator. The cell lines used were
standard and tested regularly for mycoplasma contamination and
never found positive. Primary hippocampal neurons of Fmr1 KO(2)
mice were prepared and cultured as described in de Vrij et al
(2008). For each experiment, one pregnant Fmr1 KO(2) female
mouse in the C57Bl/6 background was sacrificed, when embryos
were at day E17. Neurons were then pooled from all embryos per
litter, with average litter size being 7. The mice were housed at the
Erasmus MC animal facility (Rotterdam, the Netherlands), under
standard housing and husbandry conditions, approved by the local
animal welfare committee.
Cultured cells were transfected with the appropriate expression
constructs using polyethylenimine (PEI) (Polysciences Inc., Warring-
ton, PA, USA) for 293T cells and Lipofectamine 2000/Plus Reagent
(Invitrogen) for SH-SY5Y cells and 21-day-old primary mouse
neurons according to standard manufacturers protocols. One day
after transfection, cells were fixed with 4% formaldehyde, washed
in PBS, and then washed in a Hoechst solution (0.67 mg/ml)
(Invitrogen) before mounting in Mowiol mounting solution (Mowiol
4–88) after a final PBS wash step. For visualization of nucleoli, cells
were incubated overnight with primary nucleophosmin (NPM1)
antibody (Santa Cruz SC-6013) 1:100 in staining buffer containing
0.05 M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% Triton X-100, pH
7.4 at 4°C, followed by standard incubation with secondary anti-goat
Cy3 1:200 (Jackson Immunoresearch). Then, the cells were fixed,
stained with Hoechst and mounted in Mowiol. Imaging was done
using a Leica SP5 confocal microscope and LAS AF lite software
(Leica Microsystems). For the leptomycin B (LMB) experiments,
293T cells were seeded in 12-well plates and transfected with the
appropriate constructs using PEI as well. Two days after transfection,
50 ng/ml LMB (Sigma) was added to the cells for four hours. For cell
culture experiments, wild-type and mutant FMRP constructs were
transfected in parallel, in duplicate, in at least three independent
experiments. Cells were transfected in random order. During imag-
ing, the experimenter was blinded to the transfection conditions.
Fly stocks and husbandry
Flies were raised at 25°C, in standard rearing conditions. Following
fly strains were used for experiments:
yw; Pdf-Gal4, UAS-CD8-GFP; UAS-CD8-GFP (Ayaz et al, 2008)
w;; UAS-dfmr1wt/TM6C
w;; UAS-dfmr1DCt/TM6C
w;; UAS-dfmr1wt+NLS/TM6C
w;; UAS-dfmr1DCt+NLS/TM6C
Canton S 10 (w)
w;Pdf-Gal4 UAS-lacZ/Cyo;
UAS-RedStinger (Bloomington #8545)
ElavC155-Gal4 (Bloomington #458).
The UAS-dfmr1 strains were created using PhiC31 mediated
transgenesis in the VK33 docking site (3L, 65B2) (Venken et al,
2006). Injection of the embryos was done in-house.
Immunochemistry on fly tissue
Brains were dissected during morning hours (with genotypes in
random order) from 0- to 7-day-old adult flies and stained with
primary antibodies using the standard protocol described in Soldano
et al (2013). Primary antibodies anti-GFP (A-11222, Life Technolo-
gies, dil. 1:500), anti-bGal (A-11132, Life Technologies, dil. 1:1,000),
anti-Dfmrp (20E4, specifically generated for our lab by EMBL-MACF
Hybridoma, dil. 1:50) and Alexa Fluor secondary antibodies (Life
Technologies) were used. Images of the stained fly brains were
acquired using confocal microscopy, Nikon AIR confocal unit
mounted on a TI2000 inverted microscope (Nikon Corporations).
Quantification of axonal branching of LNv neurons
Maximum projections of the confocal stacks were analyzed using
ImageJ software. During analysis, the experimenter was blinded to
the genotypic conditions. Brains with gross mechanical damage
from dissections/staining procedure were excluded from the analy-
sis. A minimum sample size of 20 was analyzed for each genotype,
deemed sufficient to detect changes in Dfmrp activity based on
previous studies (Reeve et al, 2005, 2008). The branching areas of
small LNv axonal termini were calculated based on parameters
defined by Reeve et al (2005). The branching area was manually
outlined, starting from the first point of defasciculation of the axonal
bundle. Branching area measurements were normalized for variabil-
ity in brain size across samples by dividing branching area values
by total LNv commissure length for each brain. The Shapiro test for
normality indicated that all were normally distributed (P > 0.05)
except for the UAS-dFMR1wt sample, where the data, apart from one
outlier, were also normally distributed. ANOVA indicated that geno-
type was a significant variable explaining variation in normalized
The paper explained
Problem
Fragile X syndrome (FXS) is the most common genetic cause of intel-
lectual disability and includes features such as autistic-like behaviors,
and distinctive craniofacial phenotypes. FXS is almost always caused
by epigenetic silencing of the FMR1 gene. While the FMRP protein is
heavily studied, there is only a single confirmed disease-causing point
mutation reported thus far, making the link between functional analy-
sis of the FMRP domains and the disease difficult to analyze.
Results
We sequenced patients with FXS symptoms but no epigenetic silenc-
ing of FMR1. We found a point mutation in one patient, which causes
a frameshift in the FMRP sequence and a subsequent deletion of the
C-terminal domain. This mutation changed the localization of FMRP
from cytoplasmic to nuclear. Further analyses in human cells, and
using Drosophila as an in vivo model, demonstrated a novel and
evolutionarily conserved role for FMRP C-terminus in nuclear export.
This change in localization caused the gain of a novel function in
neurons in vivo.
Impact
Our study suggests that several FXS patients may remain undiagnosed
because clinics only screen for the epigenetic silencing of FMR1 when
FXS is suspected. Sequencing the coding region would be important
to determine whether a patient has FXS, and may therefore benefit
from future treatments. Furthermore, we identify the C-terminal
domain of the FMRP as a nuclear export domain, perhaps explaining
why naturally occurring nuclear isoforms of FMRP are generated by
alternative splicing in the C-terminus.
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axon branching values (F = 42.32, P < 0.0001). Two-tailed t-tests
using Welch’s correction were then used to compare controls with
mutant phenotypes. Similar results were obtained when a nonpara-
metric Wilcoxon test was used (not shown). Normalized branching
area values for each genotype were then analyzed based on a
two-tailed t-test with Welch’s correction, using GraphPad Prism
software. Error bars represent mean values with SD.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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